isoniazid has been researched along with Chemical Dependence in 21 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Excerpt | Relevance | Reference |
---|---|---|
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 7.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
"Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed." | 5.32 | Isoniazid hepatotoxicity among drug users: the role of hepatitis C. ( Fernández-Villar, A; Fluiters, E; Martínez-Vázquez, C; Mosteiro, M; Piñeiro, L; Sopeña, B; Ulloa, F; Vázquez, R, 2003) |
"To determine the rate of and risk factors for discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis infection in a large, multi-site study." | 3.79 | Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. ( Bethel, J; Colson, PW; Hirsch-Moverman, Y; Pettit, AC; Sterling, TR, 2013) |
" Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285,284 ($563 per person screened) was associated with DOPT ($10,274 per case prevented)." | 3.70 | Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. ( Alcabes, P; Arno, PS; Gourevitch, MN; Wasserman, WC, 1998) |
"HIV-infected adults with substance abuse (tobacco smoking, khat chewing and alcohol) should be prioritised for TB screening." | 1.43 | Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. ( Alemu, YM; Awoke, W; Wilder-Smith, A, 2016) |
"Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed." | 1.32 | Isoniazid hepatotoxicity among drug users: the role of hepatitis C. ( Fernández-Villar, A; Fluiters, E; Martínez-Vázquez, C; Mosteiro, M; Piñeiro, L; Sopeña, B; Ulloa, F; Vázquez, R, 2003) |
"Alpidem is a new anxiolytic of imidazopyridine structure which has a high affinity for the omega 1 (BZ1) modulatory site of the GABAA receptor." | 1.29 | Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence. ( Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1993) |
"Zolpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]." | 1.28 | Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. ( Morel, E; Perrault, G; Sanger, DJ; Zivkovic, B, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (38.10) | 18.7374 |
1990's | 4 (19.05) | 18.2507 |
2000's | 3 (14.29) | 29.6817 |
2010's | 5 (23.81) | 24.3611 |
2020's | 1 (4.76) | 2.80 |
Authors | Studies |
---|---|
Danna, BJ | 1 |
Harvey, AW | 1 |
Woc-Colburn, LE | 1 |
Pettit, AC | 1 |
Bethel, J | 1 |
Hirsch-Moverman, Y | 1 |
Colson, PW | 1 |
Sterling, TR | 2 |
Ricks, PM | 1 |
Hershow, RC | 1 |
Rahimian, A | 1 |
Huo, D | 1 |
Johnson, W | 1 |
Prachand, N | 1 |
Jimenez, A | 1 |
Wiebel, W | 1 |
Paul, W | 1 |
Getahun, H | 1 |
Matteelli, A | 1 |
Abubakar, I | 1 |
Aziz, MA | 1 |
Baddeley, A | 1 |
Barreira, D | 1 |
Den Boon, S | 1 |
Borroto Gutierrez, SM | 1 |
Bruchfeld, J | 1 |
Burhan, E | 1 |
Cavalcante, S | 1 |
Cedillos, R | 1 |
Chaisson, R | 1 |
Chee, CB | 1 |
Chesire, L | 1 |
Corbett, E | 1 |
Dara, M | 1 |
Denholm, J | 1 |
de Vries, G | 1 |
Falzon, D | 1 |
Ford, N | 1 |
Gale-Rowe, M | 1 |
Gilpin, C | 1 |
Girardi, E | 1 |
Go, UY | 1 |
Govindasamy, D | 1 |
D Grant, A | 1 |
Grzemska, M | 1 |
Harris, R | 1 |
Horsburgh, CR | 1 |
Ismayilov, A | 1 |
Jaramillo, E | 1 |
Kik, S | 1 |
Kranzer, K | 1 |
Lienhardt, C | 1 |
LoBue, P | 1 |
Lönnroth, K | 1 |
Marks, G | 1 |
Menzies, D | 1 |
Migliori, GB | 1 |
Mosca, D | 1 |
Mukadi, YD | 1 |
Mwinga, A | 1 |
Nelson, L | 1 |
Nishikiori, N | 1 |
Oordt-Speets, A | 1 |
Rangaka, MX | 1 |
Reis, A | 1 |
Rotz, L | 1 |
Sandgren, A | 1 |
Sañé Schepisi, M | 1 |
Schünemann, HJ | 1 |
Sharma, SK | 1 |
Sotgiu, G | 1 |
Stagg, HR | 1 |
Tayeb, T | 1 |
Uplekar, M | 1 |
van der Werf, MJ | 1 |
Vandevelde, W | 1 |
van Kessel, F | 1 |
van't Hoog, A | 1 |
Varma, JK | 1 |
Vezhnina, N | 1 |
Voniatis, C | 1 |
Vonk Noordegraaf-Schouten, M | 1 |
Weil, D | 1 |
Weyer, K | 1 |
Wilkinson, RJ | 1 |
Yoshiyama, T | 1 |
Zellweger, JP | 1 |
Raviglione, M | 1 |
Alemu, YM | 1 |
Awoke, W | 1 |
Wilder-Smith, A | 1 |
Aung, NM | 1 |
Hanson, J | 1 |
Kyi, TT | 1 |
Htet, ZW | 1 |
Cooper, DA | 1 |
Boyd, MA | 1 |
Kyi, MM | 1 |
Saw, HA | 1 |
Fernández-Villar, A | 2 |
Sopeña, B | 2 |
Vázquez, R | 1 |
Ulloa, F | 1 |
Fluiters, E | 1 |
Mosteiro, M | 1 |
Martínez-Vázquez, C | 1 |
Piñeiro, L | 1 |
Leiro, V | 1 |
Botana, M | 1 |
Douche, C | 1 |
Rougerie, M | 1 |
Perrault, G | 2 |
Morel, E | 2 |
Sanger, DJ | 2 |
Zivkovic, B | 2 |
Martin, JR | 1 |
Moreau, JL | 1 |
Jenck, F | 1 |
Pieri, L | 1 |
Gourevitch, MN | 1 |
Alcabes, P | 1 |
Wasserman, WC | 1 |
Arno, PS | 1 |
Malotte, CK | 1 |
Hollingshead, JR | 1 |
Larro, M | 1 |
Reichman, LB | 1 |
Felton, CP | 1 |
Edsall, JR | 1 |
Satpathy, R | 1 |
Das, BB | 1 |
Morrison-Smith, J | 1 |
Boehnert, MT | 1 |
Lewander, WJ | 1 |
Gaudreault, P | 1 |
Lovejoy, FH | 1 |
Brown, CV | 1 |
Stottmeier, KD | 1 |
Burkes, J | 1 |
Howard, RB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | percent (Number) |
---|---|
INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
Intervention | Participants (Count of Participants) |
---|---|
INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
Intervention | Participants (Count of Participants) |
---|---|
Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
Intervention | pmol/mg (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
Intervention | percentage of participants (Number) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
Intervention | days (Median) | |
---|---|---|
at 3 months | at 6 months | |
INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
At 3 months72558043 | At 6 months72558043 | |||||||||||
Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
INH and Vitamin B6 | 160 | |||||||||||
INH and Vitamin B6 | 79 | |||||||||||
INH and Vitamin B6 | 38 | |||||||||||
INH and Vitamin B6 | 2 | |||||||||||
INH and Vitamin B6 | 124 | |||||||||||
INH and Vitamin B6 | 90 | |||||||||||
INH and Vitamin B6 | 41 | |||||||||||
INH and Vitamin B6 | 4 | |||||||||||
INH and Vitamin B6 | 0 | |||||||||||
INH and Vitamin B6 | 1 |
2 reviews available for isoniazid and Chemical Dependence
Article | Year |
---|---|
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User | 2015 |
Advances in clinical toxicology.
Topics: Antidotes; Cathartics; Charcoal; Child; Cocaine; Deglutition; Foreign Bodies; Gastric Lavage; Humans | 1985 |
2 trials available for isoniazid and Chemical Dependence
Article | Year |
---|---|
A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Users; Ethambutol; Ethnicity; Female; | 2015 |
Incentives vs outreach workers for latent tuberculosis treatment in drug users.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Motiva | 2001 |
17 other studies available for isoniazid and Chemical Dependence
Article | Year |
---|---|
Esophageal Tuberculosis - A Mass of Confusion.
Topics: Aged; Antitubercular Agents; Deglutition Disorders; Delayed Diagnosis; Diagnosis, Differential; Dire | 2020 |
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
Topics: Adult; Alcohol Drinking; Antitubercular Agents; Canada; Female; Humans; Isoniazid; Latent Tuberculos | 2013 |
Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Case-Control Studies; CD4 Lymph | 2016 |
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit | 2017 |
Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
Topics: Adolescent; Adult; Antitubercular Agents; Female; Hepatitis C; Humans; Isoniazid; Liver; Male; Middl | 2003 |
Hepatitis C virus infection and isoniazid hepatotoxicity.
Topics: Antitubercular Agents; Hepatitis C; Humans; Isoniazid; Liver; Prognosis; Risk Factors; Substance-Rel | 2007 |
[Toxic optic neuritis: sometimes wrongly attributed to antituberculosis treatment (author's transl)].
Topics: Adult; Ethambutol; Ether; Ethyl Ethers; Female; Humans; Isoniazid; Optic Neuritis; Substance-Related | 1981 |
Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bicuculline; Carbolines; Convulsants; Diazepam; Drug | 1993 |
Sarmazenil-precipitated withdrawal: a reliable method for assessing dependence liability of benzodiazepine receptor ligands.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Benzodiazepines; Convulsants; Diazepam; Drug Toleran | 1998 |
Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Cost-Benefit Analysis; Female; Humans; Isoniazid; Mal | 1998 |
Drug dependence, a possible new risk factor for tuberculosis disease.
Topics: Humans; Isoniazid; New York City; Risk; Substance-Related Disorders; Tuberculosis | 1979 |
Accidental poisoning in childhood.
Topics: Accident Prevention; Accidents; Adolescent; Child; Child, Preschool; Female; Household Products; Hum | 1979 |
Rifampicin in clinical use.
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; England; Humans; Isonia | 1975 |
Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
Topics: Animals; Drug Tolerance; Electroshock; Hypnotics and Sedatives; Injections, Intraperitoneal; Isoniaz | 1992 |
Abuse of isoniazid.
Topics: Humans; Isoniazid; Pyridoxine; Substance-Related Disorders | 1972 |
Primary drug-resistant Mycobacterium tuberculosis isolated in Massachusetts in 1972.
Topics: Adolescent; Adult; Aged; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, M | 1974 |
Editorial: Isoniazid toxicity.
Topics: Humans; Isoniazid; Pyridoxine; Substance-Related Disorders | 1974 |